Impact of Symptom Benefit and Transfusion Response on Survival in Myelofibrosis Patients Treated with Pacritinib: PERSIST-2 Landmark Survival Analysis
Ajufo H, Bewersdorf J, Harrison C, Palandri F, Mascarenhas J, Palmer J, Gerds A, Kiladjian J, Buckley S, Derkach A, Roman-Torres K, Rampal R. Impact of Symptom Benefit and Transfusion Response on Survival in Myelofibrosis Patients Treated with Pacritinib: PERSIST-2 Landmark Survival Analysis. Blood 2023, 142: 3207. DOI: 10.1182/blood-2023-177643.Peer-Reviewed Original ResearchLandmark survival analysisOverall survivalMyelofibrosis patientsNon-respondersTransfusion independenceRed blood cellsSymptom scoresOS benefitPERSIST-2Associated with OS benefitAssociated with improved OSRed blood cell transfusionAssociated with improved survivalSymptom benefitSurvival analysisEfficacy assessment periodSpleen volume reductionMedian platelet countLog-rank testMeasures of clinical benefitBAT armTotal symptom scoreUnique survival advantagesSymptom burden reductionAnemia improvement